C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery

Monday, May 31, 2021

Moleac a biopharmaceutical company based in Singapore announced the approval by the US Food and Drug Administration FDA of an investigational new drug IND application for MLC in traumatic brain injury TBI Moleac is dedicated in finding developing and...

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

Monday, May 31, 2021

Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes highquality medicines for the treatment of cancer metabolic autoimmune and other major diseases and AnHeart Therapeutics Co Ltd AnHeart a clin...

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

Friday, May 28, 2021

CStone Pharmaceuticals a leading biopharmaceutical company focused on researching developing and commercializing innovative immunooncology therapies and precision medicines today announced that a registrational clinical trial GEMSTONE study of the an...

FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment

Thursday, May 27, 2021

Biohaven Pharmaceutical Holding Company Ltd today announced that the US Food and Drug Administration FDA has approved NURTEC ODT rimegepant mg for the preventive treatment of migraine NURTEC ODT is indicated for adult patients with episodic migraine...

Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany

Thursday, May 27, 2021

Dynavax Technologies Corporation a biopharmaceutical company focused on developing and commercializing novel vaccines today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISA...

ProBioGen and Minapharm Pharmaceuticals Incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company

Thursday, May 27, 2021

ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGens subsidiary MiGenTra with headquarters in Berlin and access to a site in Cairo which will house its principal manufacturing plant The formation of MiGenTra accelerates Pr...

TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China

Wednesday, May 26, 2021

TransThera Biosciences Co Ltd TransThera a clinical stage biotechnology company dedicated to developing innovative therapeutics across oncology cardiovascular and inflammatory diseases with major unmet medical needs globally and in China today ann...

Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization

Wednesday, May 26, 2021

Foresee Pharmaceuticals announced today that the US Food and Drug Administration FDA has approved the New Drug Application NDA for CAMCEVI mg a readytouse month subcutaneous depot formulation of leuprolide mesylate as a treatment of advanced prostat...

Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine

Wednesday, May 26, 2021

BlueRock Therapeutics LP a leading engineered cell therapy company and a whollyowned and independently operated subsidiary of Bayer AG and Senti Biosciences Inc Senti Bio a leading gene circuit company today announced a collaboration and option agree...

Vetter Once Again Wins Axia Best Managed Companies Award

Thursday, May 27, 2021

For the second time in a row Vetter a global leading contract development and manufacturing organization CDMO has won the Axia Best Managed Companies Award The pharmaceutical service provider was again honored for its clear vision innovative approach...